About PSYLO, INC
Xylo is pioneering next-generation therapeutics designed to rewire neural circuits and restore brain function, focusing on neuroplasticity to address critical gaps in the treatment of psychiatric and neurological disorders. The company was founded in 2021 and rebranded as Xylo in 2025, with a focus on computational drug discovery and mechanism-based therapies.
Is this your company?
Claim PSYLO, INC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim PSYLO, INC & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.